NCT04909931

Brief Summary

To study efficacy of Vitamin D on outcome and disease activity ; DAS28-ESR in Rheumatoid arthritis patients at Rajavithi hospital .

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2021

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

May 11, 2021

Completed
22 days until next milestone

First Posted

Study publicly available on registry

June 2, 2021

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 15, 2022

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

January 7, 2025

Status Verified

February 1, 2022

Enrollment Period

1 year

First QC Date

May 11, 2021

Last Update Submit

January 3, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • To study efficacy of vitamin D on disease activity RA patients at Rajavithi hospital

    Determine disease activity by DAS28-ESR in relation with vitamin D supplementation.

    12 weeks

  • To study efficacy of vitamin D on IL-6 in RA patients at Rajavithi hospital

    DAS-28 ESR measure from swollen joint count, tender joint count, ESR and patient global assessment

    12 weeks

Study Arms (2)

vitamin D supplementation group

EXPERIMENTAL

First arm ; add on vitamin D 40,000 IU/week for 12 weeks

Drug: Vitamin D 2

second arm

EXPERIMENTAL

add on placebo

Drug: Placebo

Interventions

Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks

vitamin D supplementation group

Second arm : add on placebo for 12 weeks

second arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \> 18 yrs old
  • RA diagnosed by ACR/EULAR 2010
  • low to moderate disease activity
  • on stable NSAIDs and DMARDs for at least 1 month
  • Received Prednisolone less than or equal to 7.5 mg/day
  • serum calcium, phosphorus and ALP are within normal limit.

You may not qualify if:

  • Chronic kidney disease stage 3 or higher
  • History of TB
  • History of Chronic liver disease
  • Pregnancy or breast-feeding
  • adjustment of immuno-suppressive drugs, steroid
  • other connective tissue disease
  • Vitamin D allergy
  • received other drugs which have vitamin D component
  • serum Vitamin D less than 10 ng/mL

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rajavithi hospital

Bangkok, Bangkok, Thailand

Location

Related Publications (3)

  • Polasik K, Piotrowska E, Lipinska B, Witkowski JM, Bryl E, Tukaj S. Vitamin D status in patients with rheumatoid arthritis: a correlation analysis with disease activity and progression, as well as serum IL-6 levels. Acta Biochim Pol. 2017;64(4):667-670. doi: 10.18388/abp.2017_1636. Epub 2017 Dec 5.

    PMID: 29202486BACKGROUND
  • Gopal K, Thevarajah M, Ng CM, Raja J. Effects of vitamin D on disease activity and serum interleukin-6 in rheumatoid arthritis. Int J Rheum Dis. 2019 May;22(5):834-841. doi: 10.1111/1756-185X.13484. Epub 2019 Feb 6.

    PMID: 30729713BACKGROUND
  • Aslam MM, John P, Bhatti A, Jahangir S, Kamboh MI. Vitamin D as a Principal Factor in Mediating Rheumatoid Arthritis-Derived Immune Response. Biomed Res Int. 2019 May 7;2019:3494937. doi: 10.1155/2019/3494937. eCollection 2019.

    PMID: 31205940BACKGROUND

MeSH Terms

Conditions

Arthritis, Rheumatoid

Interventions

Ergocalciferols

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Sirilak Nunthiyakul, Medicine

    Department of Medical Services Ministry of Public Health of Thailand

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 11, 2021

First Posted

June 2, 2021

Study Start

May 1, 2021

Primary Completion

May 15, 2022

Study Completion

December 1, 2022

Last Updated

January 7, 2025

Record last verified: 2022-02

Locations